Akshit Chitkara, MD, discusses outcomes with IO doublet therapy by dedifferentiation status and histologic grade in ccRCC.
Akshit Chitkara, MD
Advertisement
Akshit Chitkara, MD, is a hematology-oncology fellow at Sidney Kimmel Cancer Center.
Articles by Akshit Chitkara, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5